Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QN-023a in Relapsed/Refractory AML
NCT05665075Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QN-023a in acute myeloid leukemia (AML), sponsored by Zhejiang University. Primary endpoints: Treatment-Emergent Adverse Events at 2 years, Incidence of dose adjustment or discontinuation due to NK cell toxicities at 2 years and 2 more. Started Dec 2022; status: recruiting.
02
Drugs
QN-023a
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05665075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05665075.